New publication: CHRNG-related nonlethal multiple pterygium syndrome: Muscle imaging pattern and clinical, histopathological, and molecular genetic findings

A group of investigators from the Sant Joan de Deu hospital in Barcelona (Carrera, Natera and Nascimento) led a comprehensive study looking at muscle outcomes for patients with defects in the gamma-subunit of the acetylcholine receptor. In humans, the gamma subunit is only expressed before birth and for a short time afterwards. Biallelic loss-of-function mutations are believed to cause neuromuscular transmission failure in utero, resulting in fewer or no fetal movements and multiple joint contractures, or a prenatal myasthenic syndrome. After a certain stage in development, the gamma subunit is no longer required and completely replaced by the so-called adult epsilon subunit, enabling neuromuscular transmission to be restored. Thereafter the clinical course is typically stable. In individuals surviving beyond this point, the disorder is often known as Escobar syndrome or nonlethal multiple pterygium syndrome (MPS) and requires differentiating from other forms of arthrogryposis multiplex congenita. This comprehensive overview looked at the long-term outcomes of the condition, assessing clinical, biopsy and MRI findings as well as molecular genetic features, and identified long-term changes to the muscle that may be of functional relevance for the patients.

The study was published in the American Journal of Medical Genetics and the publication is now available at the journal website.

Communicated by Daniel Natera

Carrera-García L, Natera-de Benito D, Dieterich K, de la Banda MGG, Felter A, Inarejos E et al.
CHRNG-related nonlethal multiple pterygium syndrome: Muscle imaging pattern and clinical, histopathological, and molecular genetic findings.
Am. J. Med. Genet. A. 2019.
PMID: 30868735
DOI: 10.1002/ajmg.a.61122

Abstract

Mutations in the CHRNG gene cause autosomal recessive multiple pterygium syndrome (MPS). Herein we present a long-term follow-up of seven patients with CHRNG-related nonlethal MPS and we compare them with the 57 previously published patients. The objective is defining not only the clinical, histopathological, and molecular genetic characteristics, but also the type and degree of muscle involvement on whole-body magnetic resonance imaging (WBMRI). CHRNG mutations lead to a distinctive phenotype characterized by multiple congenital contractures, pterygium, and facial dysmorphism, with a stable clinical course over the years. Postnatal abnormalities at the neuromuscular junction were observed in the muscle biopsy of these patients. WBMRI showed distinctive features different from other arthrogryposis multiple congenita. A marked muscle bulk reduction is the predominant finding, mostly affecting the spinal erector muscles and gluteus maximus. Fatty infiltration was only observed in deep paravertebral muscles and distal lower limbs. Mutations in CHRNG are mainly located at the extracellular domain of the protein. Our study contributes to further define the phenotypic spectrum of CHRNG-related nonlethal MPS, including muscle imaging features, which may be useful in distinguishing it from other diffuse arthrogryposis entities.

escobar

Read next...

https://lochmullerlab.org/files/cropped-LochmullerLab_web.jpg

Lochmüller Lab Welcomes New Students

Our lab is growing! We are excited to introduce two new students who have joined the Lochmüller Lab this fall.   Kelly Ho Kelly has...
JND8-4_announcement

Latest Issue of the Journal of Neuromuscular Diseases Now Available – July 2021

The Journal of Neuromuscular Diseases (JND) has announced the publication of a new issue of the journal!     Volume 8, Issue 4 of the JND contains a record number 30 items comprised...
meetClinicalTeam

Meet the Lochmüller Lab Clinical Team

Neuromuscular Clinic for adult patients at The Ottawa Hospital (TOH) Civic Campus As part of the team led by Dr. Jodi Warman Chardon, Hanns sees...
1by1treatabolome

Special issue of the Journal of Neuromuscular Diseases is devoted to the Treatabolome, designed to shorten diagnosis-to-treatment time for patients with rare diseases

In 2019, as part of the European Solve-RD project, Hanns Lochmüller, Gisèle Bonne and Rachel Thompson launched the Treatabolome, an initiative designed to extract details...
ProDGNE RGB-01

ProDGNE: Research Project to Develop an Innovative Therapeutic Compound to Treat GNE Myopathy

The Lochmüller Lab is proud to share its involvement in ProDGNE , a three-year transnational pre-clinical research project which aims to develop an innovative therapeutic...
Neuromuscular junction and animal models

Meet the lab’s two new members

Our lab is growing! We are excited to introduce two new members who have joined the Lochmüller lab this winter. Daniel O'Neil Daniel holds a...